Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumor that usually occurs in children between 5 and 7. This fast-growing tumor forms in the part of a child’s brain responsible forRead More…
Gut Microbiome Plays a Key Role in CAR-T Cell Cancer Immunotherapy
In a recent study, researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the Weizmann Institute of Science in Israel, the University of South Florida, and the University of Texas MDRead More…
Knockdown of Two Genes by CRISPR-Cas9 to Improve T-Cell Therapy in Solid Tumors
Since the world’s first chimeric antigen receptor (CAR)-T cell therapy was approved for marketing in 2017, the Food and Drug Administration (FDA) has approved a total of six CAR-T cell therapies toRead More…
Overcoming On-Target Off-Tumor Toxicity of CAR T-Cell Therapy for Solid Tumors
The success of CAR T cells in treating hematologic malignancies has provided impetus for the development of CAR T therapies in solid tumors. The biggest obstacle to the development of CAR TRead More…
Personalized Stimulation on CAR-T Cells During Manufacture Promises to Make Personalized CAR-T Cell Therapy A Reality
Since 2017, when chimeric antigen receptor-T cells (CAR-T) were approved by the US Food and Drug Administration (FDA) as the first modified cell for the treatment of leukemia, five similar products haveRead More…
Dual-Target CAR-T Cell Therapy Is Driving Next Wave of Innovation in Immunotherapy
Chimeric antigen receptor (CAR) T cells have been remarkably successful in the treatment of relapsed hematologic malignancies, such as acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM). CD19 andRead More…
STAb-T Cell Therapy: Promising Treatment for T-Cell Acute Lymphoblastic Leukemia
PIn a new study, Spanish researchers have developed a cell therapy for a type of leukemia for which there are currently few treatment options. This STAb-T cell therapy is based on STAb-TRead More…
Whole-Body PET Scans Reveal Complex Characterization of Immunotherapy Response in Cancer Patients
Immune checkpoint inhibitors activate the host immune system to defend against tumors, and although this cancer therapy has shown remarkable success today, the chances of patient response to the therapy are stillRead More…
CAR-T Cells Targeting Tumor Macrophages Show Promise for Treating a Range of Solid Tumors
In a recent study, researchers from the Icahn School of Medicine at Mount Sinai show that a new cancer immunotherapy that uses one type of immune cell to kill another type ofRead More…
T Cells Expressing Alloimmune Defense Receptor (ADR) Show Promise in Preventing Graft-Versus-Host Disease and Cancer Recurrence
In a recent study, researchers from Baylor College of Medicine and Boston Children’s Hospital, among other institutions, genetically modified T cells to control two major life-threatening complications, graft-vs-host disease (GvHD) and cancerRead More…